Ibrance, a promising new drug to treat advanced breast cancer in older women, is being hailed as impressive and having "blockbuster sales potential" by financial analysts. The drug is a pioneering hormone-based therapy for such cancers, but it's only for women who fit a specific health profile.
The medication is for postmenopausal women whose metastatic cancer tests negative for a specific protein, HER2, but tests positive for an estrogen receptor, according to Ibrance's website. Patients also cannot have received previous hormonal treatment for cancer. Ibrance works by inhibiting specific...
Also read: UPS Tests Drone-Based Package Deliveries